{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:22:35Z","timestamp":1793658155658,"version":"4.5.1"},"reference-count":40,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573145\uff1b82372945\uff1b82030092"],"award-info":[{"award-number":["82573145\uff1b82372945\uff1b82030092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1201100"],"award-info":[{"award-number":["2021YFA1201100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaboration Program of Beijing Tianjin and Hebei","award":["22JCZXJC00120"],"award-info":[{"award-number":["22JCZXJC00120"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CLDN18.2 has emerged as a promising therapeutic target in gastric and gastro-oesophageal junction cancers. However, its clinical efficacy in pancreatic ductal adenocarcinoma (PDAC) has been modest, suggesting the presence of regulatory mechanisms impairing its efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aim to investigate how O-linked N-acetylglucosaminylation (O-GlcNAcylation) affects CLDN18.2 subcellular localisation, tumour progression and therapeutic resistance in PDAC, while exploring strategies to restore treatment sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This study used samples from patients with PDAC, along with the following models: humanised patient-derived xenograft (PDX), patient-derived organoids (PDOs), orthotopic PDO xenograft, KPC mice (LSL-KrasG12D\/+; LSL-Trp53R172H\/+; Pdx1-Cre) and KPC-Cldn18.2 knockout (KO) mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>KRAS<\/jats:italic>\n                      (Kirsten rat sarcoma viral oncogene homolog) mutation and hyperglycaemia cooperatively drive CLDN18.2 O-GlcNAcylation at T204, promoting CLDN18.2 cytoplasmic accumulation. O-GlcNAcylated CLDN18.2 promotes pancreatic cancer migration, invasion and metastases and reduces its sensitivity to anti-CLDN18.2 based targeted therapy. Mechanistically, O-GlcNAcylated CLDN18.2 exhibits reduced binding to PTP1B, leading to enhanced tyrosine phosphorylation. O-GlcNAcylated CLDN18.2 recruits\n                      <jats:italic>Src<\/jats:italic>\n                      via SH2 domain, triggering\n                      <jats:italic>Src<\/jats:italic>\n                      activation. Genetic (T204A) or pharmacological blockade of O-GlcNAcylation restores CLDN18.2 membrane localisation and suppresses tumour progression. Therapeutically, low-dose MRTX1133 (KRAS\n                      <jats:sup>G12D<\/jats:sup>\n                      inhibitor) reduces O-GlcNAcylation and synergises with CLDN18.2-targeted therapy in KRAS mutant PDAC models with minimal side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>KRAS mutations and hyperglycaemia drive O-GlcNAcylation of CLDN18.2 at its C-terminal T204 site. O-GlcNAcylated CLDN18.2 promotes poor prognosis and reduces the effectiveness of CLDN18.2-targeted therapies. Low dose MRTX1133 restores CLDN18.2 membrane localisation by reducing its O-GlcNAcylation and augments CLDN18.2-targeted therapy efficacy, offering a novel combinatorial strategy for KRAS-mutant PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-336277","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:20:29Z","timestamp":1767982829000},"page":"1169-1185","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-8159","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center\uff1bDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6330-1773","authenticated-orcid":false,"given":"Xupeng","family":"Hou","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Bai","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Chen","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Yu","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Administrative Office of National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antao","family":"Chang","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbiao","family":"Huang","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Senior Ward, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1730","authenticated-orcid":false,"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[{"name":"Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China"},{"name":"Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026061204501059000_75.6.1169.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.009"},{"key":"2026061204501059000_75.6.1169.2","doi-asserted-by":"crossref","first-page":"102719","DOI":"10.1016\/j.ctrv.2024.102719","article-title":"Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection","volume":"125","author":"Brozos-V\u00e1zquez","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026061204501059000_75.6.1169.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00874-2"},{"key":"2026061204501059000_75.6.1169.4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"2026061204501059000_75.6.1169.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"2026061204501059000_75.6.1169.6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00620-7"},{"key":"2026061204501059000_75.6.1169.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01595-w","article-title":"Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting","volume":"17","author":"Zhou","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026061204501059000_75.6.1169.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02903-0"},{"key":"2026061204501059000_75.6.1169.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3850"},{"key":"2026061204501059000_75.6.1169.10","first-page":"429","article-title":"KRAS, BRAF and gastric cancer","volume":"4","author":"Hewitt","year":"2015","journal-title":"Transl Gastrointest Cancer"},{"key":"2026061204501059000_75.6.1169.11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2591"},{"key":"2026061204501059000_75.6.1169.12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.trecan.2022.10.001","article-title":"Precision oncology provides opportunities for targeting KRAS-inhibitor resistance","volume":"9","author":"Sattler","year":"2023","journal-title":"Trends Cancer"},{"key":"2026061204501059000_75.6.1169.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-01085-5"},{"key":"2026061204501059000_75.6.1169.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05259-w","article-title":"Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis"},{"key":"2026061204501059000_75.6.1169.15","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.cmet.2023.09.009","article-title":"High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate","volume":"35","author":"Zhou","year":"2023","journal-title":"Cell Metab"},{"key":"2026061204501059000_75.6.1169.16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.ccell.2022.08.012","article-title":"Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance","volume":"40","author":"Shi","year":"2022","journal-title":"Cancer Cell"},{"key":"2026061204501059000_75.6.1169.17","doi-asserted-by":"crossref","first-page":"110946","DOI":"10.1016\/j.celrep.2022.110946","article-title":"Spatial and temporal proteomics reveals the distinct distributions and dynamics of O-GlcNAcylated proteins","volume":"39","author":"Xu","year":"2022","journal-title":"Cell Rep"},{"key":"2026061204501059000_75.6.1169.18","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.21.5999"},{"key":"2026061204501059000_75.6.1169.19","doi-asserted-by":"crossref","first-page":"155145","DOI":"10.1016\/j.prp.2024.155145","article-title":"Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion","volume":"254","author":"Angerilli","year":"2024","journal-title":"Pathol Res Pract"},{"key":"2026061204501059000_75.6.1169.20","unstructured":"Tian X , He Y , Han Z , et al . The Cytoplasmic Expression Of CLDN12 Predicts An Unfavorable Prognosis And Promotes Proliferation And Migration Of Osteosarcoma"},{"key":"2026061204501059000_75.6.1169.21","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6.93"},{"key":"2026061204501059000_75.6.1169.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020569","article-title":"Claudin-1, A Double-Edged Sword in Cancer","volume":"21","author":"Bhat","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026061204501059000_75.6.1169.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3050"},{"key":"2026061204501059000_75.6.1169.24","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.immuni.2024.04.021","article-title":"Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer","volume":"57","author":"De Sanctis","year":"2024","journal-title":"Immunity"},{"key":"2026061204501059000_75.6.1169.25","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.3390\/jcm12165394","article-title":"Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression","volume":"12","author":"Park","year":"2023","journal-title":"JCM"},{"key":"2026061204501059000_75.6.1169.26","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v14.i7.1252"},{"key":"2026061204501059000_75.6.1169.27","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue Barriers"},{"key":"2026061204501059000_75.6.1169.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.09.028"},{"key":"2026061204501059000_75.6.1169.29","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.21037\/jgo-24-326","article-title":"Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer","volume":"15","author":"Pollin","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"2026061204501059000_75.6.1169.30","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00432-022-03966-7","article-title":"KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer","volume":"149","author":"Shimozaki","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026061204501059000_75.6.1169.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.002"},{"key":"2026061204501059000_75.6.1169.32","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.22, 10.1038\/nrn.2017.89, 10.1038\/nrn.2017.87"},{"key":"2026061204501059000_75.6.1169.33","doi-asserted-by":"crossref","first-page":"216258","DOI":"10.1016\/j.canlet.2023.216258","article-title":"O-GlcNAcylation in cancer development and immunotherapy","volume":"566","author":"He","year":"2023","journal-title":"Cancer Lett"},{"key":"2026061204501059000_75.6.1169.34","doi-asserted-by":"crossref","first-page":"112796","DOI":"10.1016\/j.celrep.2023.112796","article-title":"Systematic analysis of the impact of phosphorylation and O-GlcNAcylation on protein subcellular localization","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep"},{"key":"2026061204501059000_75.6.1169.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2014.05.017"},{"key":"2026061204501059000_75.6.1169.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.779405"},{"key":"2026061204501059000_75.6.1169.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-021-00750-x","article-title":"Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition","volume":"19","author":"Ortiz","year":"2021","journal-title":"Cell Commun Signal"},{"key":"2026061204501059000_75.6.1169.38","doi-asserted-by":"crossref","first-page":"1136227","DOI":"10.3389\/fonc.2023.1136227","article-title":"Claudin and pancreatic cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"2026061204501059000_75.6.1169.39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.apsb.2020.03.008","article-title":"ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression","volume":"10","author":"Yuan","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"2026061204501059000_75.6.1169.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.001"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-336277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:52:37Z","timestamp":1781265157000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-336277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/gutjnl-2025-336277"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-336277","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]}}}